OTCMKTS:IPSEY - IPSEN S A/S Stock Price, Forecast & News

$13.46

-0.01 (-0.07 %)

(As of 03/30/2020 04:00 PM ET)

Add

Compare

Today's Range

$13.40

Now: $13.46▼

$13.46

50-Day Range

$9.76

MA: $15.54▼

$19.15

52-Week Range

$9.10

Now: $13.46▼

$34.86

Volume1,299 shs

Average Volume2,863 shs

Market Capitalization$4.51 billion

P/E Ratio7.12

Dividend Yield1.48%

Beta0.65

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:IPSEY

Previous Symbol

CUSIPN/A

CIKN/A

Webhttp://www.ipsen.com/

Phone33-01-58-33-50-00

Debt

Debt-to-Equity RatioN/A

Current Ratio0.93

Quick Ratio0.78

Price-To-Earnings

Trailing P/E Ratio7.12

Forward P/E Ratio5.83

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.02 billion

Price / Sales1.50

Cash Flow$2.40 per share

Price / Cash Flow5.60

Book Value$5.86 per share

Price / Book2.30

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees5,700

Outstanding Shares335,177,000

Market Cap$4.51 billion

Next Earnings DateN/A

OptionableNot Optionable

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

IPSEN S A/S (OTCMKTS:IPSEY) Frequently Asked Questions

How has IPSEN S A/S's stock been impacted by COVID-19 (Coronavirus)?

IPSEN S A/S's stock was trading at $14.4150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPSEY shares have decreased by 6.6% and is now trading at $13.46. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IPSEN S A/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IPSEN S A/S in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for IPSEN S A/S.

Has IPSEN S A/S been receiving favorable news coverage?

News coverage about IPSEY stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IPSEN S A/S earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutIPSEN S A/S.

Who are some of IPSEN S A/S's key competitors?

Some companies that are related to IPSEN S A/S include Quidel (QDEL), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Lantheus (LNTH), Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX) and Riot Blockchain (RIOT).

What other stocks do shareholders of IPSEN S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IPSEN S A/S investors own include Aeglea Bio Therapeutics (AGLE), Applied Genetic Technologies (AGTC), Heat Biologics (HTBX), Nektar Therapeutics (NKTR), Reata Pharmaceuticals (RETA), Revance Therapeutics (RVNC), Sesen Bio (SESN), Spirit of Texas Bancshares (STXB), United Therapeutics (UTHR) and AMBEV S A/S (ABEV).

Who are IPSEN S A/S's key executives?

IPSEN S A/S's management team includes the following people:

Mr. David D. Meek, CEO & Director (Age 56)
Mr. Aymeric Le Chatelier, Exec. VP & CFO (Age 50)
Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 53)
Dr. Alexandre P. Lebeaut, Exec. VP of R&D and Chief Scientific Officer (Age 62)
Ms. Eugenia Litz, VP of Investor Relations

What is IPSEN S A/S's stock symbol?

IPSEN S A/S trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of IPSEN S A/S?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IPSEN S A/S's stock price today?

One share of IPSEY stock can currently be purchased for approximately $13.46.

How big of a company is IPSEN S A/S?

IPSEN S A/S has a market capitalization of $4.51 billion and generates $3.02 billion in revenue each year. The company earns $-56,780,000.00 in net income (profit) each year or $1.89 on an earnings per share basis. IPSEN S A/S employs 5,700 workers across the globe. View additional information about IPSEN S A/S.

What is IPSEN S A/S's official website?

The official website for IPSEN S A/S is http://www.ipsen.com/.

How can I contact IPSEN S A/S?

IPSEN S A/S's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]

MarketBeat Community Rating for IPSEN S A/S (OTCMKTS IPSEY)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		165 (Vote Outperform)
Underperform Votes:		187 (Vote Underperform)
Total Votes:		352

MarketBeat's community ratings are surveys of what our community members think about IPSEN S A/S and other stocks. Vote "Outperform" if you believe IPSEY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPSEY will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Trading Stocks - What are percentage gainers?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.